Aurealis Therapeutics

Aurealis Therapeutics is a clinical-stage Swiss-Finnish synthetic biology company focused on developing curative multi-target cell and gene therapies.

The company aims to address chronic wounds, deadly cancers, and inflammatory diseases using genetically modified lactic acid bacteria as a core platform. Founded in 2010 and operating from Kuopio, Finland, and Zug/Basel, Switzerland, Aurealis Therapeutics has raised approximately $40.3 million in funding. The company is advancing a pipeline of innovative therapies, including AUP-16, which is in Phase 2 clinical trials for chronic wounds, and AUP-55, a pre-clinical candidate targeting ovarian cancer and peritoneal carcinomatosis. Aurealis Therapeutics employs around 17 people and actively seeks strategic partnerships to facilitate market entry and commercialization of its therapies. The company is dedicated to creating impactful treatments for patients with high unmet medical needs in the healthcare sector.